title: Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.
abstract: The management of ovarian cancer is not only multifactorial, but also patient-specific. Different treatment modalities lead to varying levels of toxicity and individual patient responses, necessitating a personalized approach to each treatment plan. Surgical treatment along with first-line and salvage chemotherapies, are standard modalities but recent innovations in chemotherapy delivery and innovative therapy with mechanism of action are reviewed in this article. Extensive experience with standard chemotherapy has outlined algorithms for managing various toxicities. The focus of treatment may ultimately point towards palliative care and clinicians must be comfortable and well versed in addressing this important option. Overall, management of ovarian cancer requires a multi-faceted approach, keeping the patients' overall health, curative goals and well-being at the forefront. It is nearly impossible to detail exact management plans for every possible toxicity for every patient; formulating personalized treatment plans should be based on evidence and clinician experience, all part of the art of medicine. The objective of this article is to highlight the most frequently encountered and most limiting toxicities of current standard therapies for epithelial ovarian cancer.
authors.affiliation: Department of Obstetrics & Gynecology, Lankenau Hospital, 100 East Lancaster Avenue, Wynnewood, PA 19004, USA. stamplerk@mlhs.org
authors.forename: Kate M
authors.initials: KM
authors.lastname: Stampler
authors.forename: David O
authors.initials: DO
authors.lastname: Holtz
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Dunton
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D010166:Palliative Care; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents